TP53 and cancer: Patients with higher expression levels of TP53 have significantly worse DFS prognoses than those with lower expression levels of TP53 in two cancer types (UCS and OV), but have better DFS prognoses in HNSC (log-rank test, unadjusted P-value < 0.05).